ENVVENO MEDICAL CORP

NVNONASDAQ

🏆 #3775 by market capEarnings Oct 28 · PostUS Equity

$11.13▲ $0.95 (+8.54%)

Live

1h—

24h▲ 8.5%

7d▲ 5.9%

14d▲ 5.9%

30d▲ 0.3%

1y▼ 93.1%

🏦Market Cap

$7M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

100.0%

High

💵FCF Margin

—

⚖️P/S Ratio

38.9x

Expensive

Otter Score

Fair

Trading Snapshot

Day Range: $11.09 – $11.23
52-Week Range: $8.67 – $179.55
Volume: $3.28B
Avg Volume: $3.09B
Shares Outstanding: 670,000
Next Earnings: Sep 3, 2026

Fundamentals Snapshot

Annual Revenue: $195,366
Last Q Revenue: $51,069
P/E Ratio: —
P/S Ratio: 38.9x
EPS (TTM): $-25.19
Dividend Yield: —

Why Investors Own NVNO

✓High-growth profile — revenue up +22.1% YoY with expanding US Equity exposure.
✓Healthy economics — 30% gross margin and 24% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$195,366▲ +26.1% YoY

Gross Margin (TTM)

30.2%▲ +1.1% YoY

Operating Income (TTM)

$51,186▲ +26.1% YoY

Free Cash Flow (TTM)

$46,497▲ +26.1% YoY

About ENVVENO MEDICAL CORP

enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.

🦦